Uncategorized
Phase 3 clinical trial strategy developed for Inotek’s trabodenoson
Inotek Pharmaceuticals intends to begin a phase 3 clinical trial of its leading glaucoma drug candidate, trabodenoson, in the fourth quarter of 2015, the company announced in a press release.The phase 3 clinical trial design incorporates feedback from an end-of-phase 2 meeting between the FDA and Inotek.